Susan Branford

Summary

Affiliation: South Australia
Country: Australia

Publications

  1. Branford S, Yeung D, Prime J, Choi S, Bang J, Park J, et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood. 2012;119:4264-71 pubmed publisher
    ..Long doubling times observed with mutations in CP allow time for intervention. A short doubling time for a patient in CP should raise the suspicion of nonadherence. ..
  2. Branford S, Kim D, Soverini S, Haque A, Shou Y, Woodman R, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30:4323-9 pubmed publisher
    ..Prospective studies may determine whether close monitoring or alternative therapies are warranted for patients with minimal initial molecular response. ..
  3. Branford S. Monitoring after successful therapy for chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:105-10 pubmed publisher
  4. Branford S, Yeung D, Ross D, Prime J, Field C, Altamura H, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818-24 pubmed publisher
    ..The Tops trial was registered at http://www.clinicaltrials.gov as NCT00124748. The TIDEL I trial was registered at www.ANZCTR.org.au as ACTRN12607000614493. The TIDEL II trial was registered at www.ANZCTR.org.au as ACTRN12607000325404. ..
  5. Branford S, Wang P, Yeung D, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease. Blood. 2018;: pubmed publisher
    ..Future refined biomarker testing of specific variants will likely provide prognostic information to facilitate a risk-adapted therapeutic approach. ..
  6. Branford S. Monitoring and defining early response: Where to draw the line?. Best Pract Res Clin Haematol. 2016;29:284-294 pubmed publisher